Seres reports 80% Phase 1b response rate for SER-155 in immunotherapy-related enterocolitis

Seres Therapeutics said SER-155 delivered an 80% Phase 1b response rate in immunotherapy-related enterocolitis, with 12 of 15 patients responding without systemic immunosuppression. The result supports further study.

Detected & updated continuously · Source: Nebula